

Experiment Number: 97011-17
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/18/2014
Time Report Requested: 17:29:27
First Dose M/F: NA / NA
Lab: MBA

C Number: C97011B
Lock Date: 09/18/2000
Cage Range: All
Date Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: All
Study Gender: Both
PWG Approval Date: NONE

Experiment Number: 97011-17
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/18/2014
Time Report Requested: 17:29:27
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Moribund Sacrifice		1
Natural Death		4
Survivors		
Accidentally Killed	1	
Terminal Sacrifice	14	10
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(14)
Centrilobular, Vacuolization Cytoplasmic	1 [1.0]	
Hepatocyte, Inflammation, Chronic Active, Focal		1 [1.0]
Mesentery	(1)	(0)
Fat, Necrosis, Focal	1 [4.0]	
Stomach, Forestomach	(15)	(13)
Tooth	(1)	(0)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(11)
Subcapsular, Hyperplasia, Focal		1 [1.0]
Zona Glomer, Hyperplasia, Focal	2 [1.0]	3 [1.0]
Zona Reticul, Vacuolization Cytoplasmic, Focal	3 [1.0]	2 [1.0]
Adrenal Medulla	(14)	(11)
Pituitary Gland	(12)	(11)

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:27

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
Thyroid Gland	(14)	(13)
Ectopic Thymus		1 [1.0]
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Epididymis	(15)	(13)
Hypospermia		10 [3.0]
Seminal Vesicle	(0)	(3)
Atrophy, Diffuse		1 [3.0]
Dilatation		2 [2.0]
Testes	(15)	(12)
Germinal Epith, Degeneration	1 [1.0]	11 [3.0]
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(12)
Myeloid Cell, Hyperplasia		1 [4.0]
Lymph Node, Mandibular	(15)	(12)
Lymph Node, Mediastinal	(11)	(10)
Lymph Node, Mesenteric	(15)	(12)
Spleen	(15)	(12)
Congestion		1 [3.0]
Hematopoietic Cell Proliferation	4 [1.0]	11 [2.0]
Lymph Follic, Depletion Cellular, Diffuse		1 [4.0]
Thymus	(15)	(10)
Atrophy, Focal		2 [1.0]
INTEGUMENTARY SYSTEM		
None		
MUSCULOSKELETAL SYSTEM		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:27

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
Bone	(0)	(1)
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(14)
Alveolar Epith, Hyperplasia, Focal		3 [1.0]
Alveolus, Edema, Focal		1 [3.0]
Alveolus, Inflammation, Chronic Active, Focal		6 [1.0]
Perivascular, Infiltration Cellular, Lymphocyte		1 [1.0]
SPECIAL SENSES SYSTEM		
Lacrimal Gland	(0)	(1)
URINARY SYSTEM		
Kidney	(15)	(13)
Renal Tubule, Dilatation, Focal		1 [1.0]
Renal Tubule, Inflammation, Chronic Active, Focal		1 [1.0]
Urinary Bladder	(15)	(12)

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 97011-17
 Test Type: 26-WEEK
 Route: GAVAGE
 Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
 CAS Number: 6055-19-2

Date Report Requested: 10/18/2014
 Time Report Requested: 17:29:27
 First Dose M/F: NA / NA
 Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Natural Death		1
Survivors		
Moribund Sacrifice		2
Terminal Sacrifice	15	12
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Esophagus	(0)	(1)
Periesoph Tiss, Cyst, Squamous, Focal		1 [2.0]
Liver	(15)	(15)
Centrilobular, Hepatocyte, Vacuolization Cytoplasmic, Focal	2 [1.5]	
Hepatocyte, Inflammation, Chronic Active, Focal	1 [1.0]	
Hepatocyte, Necrosis, Focal	2 [1.0]	
Hepatocyte, Vacuolization Cytoplasmic, Focal	2 [1.0]	
Mesentery	(1)	(0)
Fat, Hemorrhage, Focal	1 [2.0]	
Fat, Inflammation, Chronic Active, Focal	1 [2.0]	
Stomach, Forestomach	(15)	(15)
Tooth	(1)	(0)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:27

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Subcapsular, Hyperplasia, Focal	7 [1.1]	2 [1.0]
Zona Reticul, Vacuolization Cytoplasmic, Diffuse	1 [3.0]	1 [2.0]
Zona Reticul, Vacuolization Cytoplasmic, Focal	11 [1.2]	9 [1.4]
Adrenal Medulla	(15)	(15)
Pituitary Gland	(15)	(14)
Thyroid Gland	(14)	(14)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Ovary	(15)	(15)
Atrophy	3 [1.0]	6 [1.3]
Periovarn Tiss, Inflammation, Acute, Focal		1 [2.0]
Periovarn Tiss, Inflammation, Chronic Active, Diffuse	1 [2.0]	
Uterus	(15)	(14)
Endometrium, Hyperplasia, Cystic	12 [1.3]	13 [1.1]
Endometrium, Inflammation, Acute, Focal		1 [1.0]
Hydrometra	2 [3.0]	1 [3.0]

HEMATOPOIETIC SYSTEM

Bone Marrow	(15)	(14)
Myeloid Cell, Hyperplasia		3 [1.7]
Lymph Node, Mandibular	(15)	(14)
Lymph Node, Mediastinal	(14)	(9)
Lymph Node, Mesenteric	(15)	(15)
Spleen	(15)	(14)
Hematopoietic Cell Proliferation	3 [2.0]	13 [2.0]
Pigmentation	5 [1.2]	5 [1.2]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:27

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Thymus	(15)	(14)
Atrophy, Diffuse	1 [3.0]	1 [3.0]
Atrophy, Focal	2 [1.0]	1 [1.0]
INTEGUMENTARY SYSTEM		
Skin	(3)	(3)
MUSCULOSKELETAL SYSTEM		
Bone	(0)	(1)
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar Epith, Hyperplasia, Focal		1 [1.0]
Alveolus, Hemorrhage, Focal	1 [1.0]	
Alveolus, Inflammation, Chronic Active, Focal		5 [1.0]
Congestion, Diffuse		1 [3.0]
Trachea	(0)	(1)
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(14)
Urinary Bladder	(14)	(14)

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)